(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
5 Language Learning Applications - 2Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- 3The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- 4It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
- 5How to watch 'A Charlie Brown Christmas' for less with this Apple TV Black Friday deal
- 21 Incredibly Entertaining Contemplations To Observe Consistently
- It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Pick Your #1 Sort Of Espresso
- Fiber is something most people could use more of. But experts advise caution with 'fibermaxxing'
- Astronomers spot white dwarf star creating a colorful shockwave
- Worldwide Objections Ideal For A Golf Outing
- Vote In favor of Your Favored Kind Of Bites
- Help Your Business with Master Web based Promoting Arrangements
